Related Experiment Video
Updated: Apr 12, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results
Fable Zustovich1, Alessandra Ferro, Giuseppe Lombardi
1Veneto Institute of Oncology IRCCS, Padova, Italy.
Background:
Bevacizumab is a recombinant humanized monoclonal antibody that obstructs the vascular endothelial growth factor (VEGF) pathway. Despite its extensive employment in the treatment of primary tumors of the brain, experience of brain metastatic disease, a frequent complication in patients with lung cancer, is very limited. On the basis of the strong antiedemigenous effect and no risk of intracranial bleeding, we administered a bevacizumab-based chemotherapy to patients with non-small-cell lung cancer (NSCLC) and symptomatic metastatic brain lesions who were not suitable candidates for a specific local therapy.
Methods:
The patients received bevacizumab 7.5 mg/kg and cisplatin 75 mg/m(2) on day 1, and gemcitabine 1,250 mg/m(2) on days 1 and 8, every 21 days.
Results:
We studied 13 patients with clinical and radiological progressive brain metastases; the majority had a treatment-naïve disease. Bevacizumab-based chemotherapy was found to be well tolerated and effective: progression-free survival (PFS) was 9.1 months (range: 0.9-39.2+) and overall survival (OS) was 9.6 months (range 3-41.5+).
Conclusions:
Bevacizumab-based therapy proved to be feasible and safe. The PFS and the OS data are very encouraging as well as the symptomatic benefit due to bevacizumab's high capacity to provide a long-lasting decrease of perilesional edema.
Insights
Bevacizumab chemotherapy effectively treated brain metastases in lung cancer patients, showing encouraging survival rates and reducing edema. This approach is safe and feasible for those ineligible for local therapies.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Bevacizumab targets the vascular endothelial growth factor (VEGF) pathway.
- Limited data exists on bevacizumab for brain metastases in lung cancer.
- Bevacizumab demonstrates anti-edema effects with low intracranial bleeding risk.
Purpose of the Study:
- To evaluate the efficacy and safety of bevacizumab-based chemotherapy for non-small-cell lung cancer (NSCLC) with symptomatic brain metastases.
- To assess outcomes in patients unsuitable for local therapies.
Main Methods:
- A bevacizumab-based chemotherapy regimen was administered to 13 patients with progressive brain metastases.
- Treatment involved bevacizumab (7.5 mg/kg), cisplatin (75 mg/m2), and gemcitabine (1,250 mg/m2) every 21 days.
Main Results:
- The therapy was well-tolerated and effective in treatment-naïve patients.
- Median progression-free survival (PFS) was 9.1 months.
- Median overall survival (OS) was 9.6 months.
Conclusions:
- Bevacizumab-based therapy is a feasible and safe treatment option for NSCLC brain metastases.
- Encouraging PFS and OS data were observed.
- Bevacizumab significantly reduced perilesional edema, providing symptomatic benefit.
